RESUMO
BACKGROUND: The data, presented here, come from samples collected during three research projects which aimed to assess the impact of land-use type on Arbuscular Mycorrhizal Fungi (AMF) diversity and community composition in pastures of Terceira Island (Azores, Macaronesia, Portugal) and also in the native forest of two Azorean Islands (Terceira and São Miguel; Azores, Macaronesia, Portugal). Both projects contributed to improving the knowledge of AMF community structure at both local and regional scales. NEW INFORMATION: Little is known on the AMF communities from Azores islands and this study reports the first survey in two Azorean Islands (Terceira and São Miguel). A total of 18,733 glomeromycotan spores were classified at the species level from 244 field soil samples collected in three different habitat types - native forests (dominated by Juniperus brevifolia and Picconia azorica), semi-natural and intensively-managed pastures. Thirty-seven distinct spore morphotypes, representing ten glomeromycotan families, were detected. Species of the family Acaulosporaceae dominated the samples, with 13 species (38% of the taxa), followed by Glomeraceae (6 spp.), Diversisporaceae (4 spp.), Archaeosporaceae (3 spp.), Claroideoglomeraceae (3 spp.), Gigasporaceae (3 spp.), Ambisporaceae and Paraglomeraceae, both with the same number of AMF species (2 spp.), Sacculosporaceae (1 sp.) and Entrophospora (family insertae sedis). Members of the family Acaulosporaceae occurred almost exclusively in the native forests especially associated with the Picconia azorica rhizosphere, while members of Gigasporaceae family showed a high tendency to occupy the semi-natural pastures and the native forests of Picconia azorica. Members of Glomeraceae family were broadly distributed by all types of habitat which confirm the high ecological plasticity of this AMF family to occupy the more diverse habitats.
RESUMO
BACKGROUND: People with schizophrenia frequently have cognitive dysfunction, which does not respond to pharmacological interventions. Varenicline has been identified as a potential treatment option for nicotinic receptor dysfunction with a potential to treat cognitive impairment in schizophrenia. METHODS: We conducted a systematic review of Pubmed, Embase, Psycinfo, CINAHL and the Cochrane Schizophrenia Trial Registry for randomised controlled trials of varenicline in people with schizophrenia for cognitive dysfunction. We excluded trials among people with dementia. We then undertook a meta-analysis with the primary outcome of difference in change of cognitive measures between varenicline and placebo as well as secondary outcomes of difference in rates of adverse events. We conducted a sensitivity analysis on smoking status and study duration. RESULTS: We included four papers in the meta-analysis (n = 339). Varenicline was not superior to placebo for overall cognition (SMD = -0.022, 95% CI -0.154-0.110; Z = -0.333; p = 0.739), attention (SMD = -0.047, 95% CI -0.199-0.104; Z = -0.613; p = 0.540), executive function (SMD = -0.060, 95% CI -0.469-0.348; Z =- 0.290; p = 0.772) or processing speed (SMD = 0.038, 95% CI -0.232-0.308; Z = 0.279; p = 0.780). There was no difference in psychotic symptoms, but varenicline was associated with higher rates of nausea. Sensitivity analyses for smoking status and study duration did not alter the results. CONCLUSION: Within the present literature, varenicline does not appear to be a useful target compound for improving cognitive impairment in schizophrenia. Based on these results, a trial would need over 2500 participants to be powered to show statistically significant findings.
